Objective. To evaluate the survival of patients with malignant central nervous system (CNS) tumors related to prognostic variables and type of treatment. Methods. The Cancer Registry of the Istituto Nazionale Neurologico C. Besta was the source of cases for the study. Malignant tumors as defined by the fifth digit code "3" of the International Classification of Disease for Oncology (ICDO) were included. We had 198 cases (170 adults and 28 children) diagnosed during 1997 and actively followed-up until 31 December 1999. Results. The median follow-up was 21 months. Mortality rates were 51% for adults and 39% for children. In the univariate analysis, age, histological type and type of surgery were the most significant prognostic factors for adult patients. Median survival time from diagnosis were 8 (95% CI 5-11) and 11 months (95% CI 8-14) for patients aged >65 and 55-65 years, respectively. Median survival time was not reached by younger patients. Median survival times for anaplastic astrocytomas and glioblastomas were 13 (95%CI 6-20) and 14 months (95%CI 11-17), respectively. During follow-up, oligoastrocytoma patients did not reach the median survival. Survival probability was significantly lower for patients with cerebral biopsy or partial surgery compared with radical surgery: median survival time was 7 (95%CI 4-10), 11 (95%CI 8-14), and 20 months (95%CI 18-24), respectively. Chemiotherapy improved survival from 6 (95%CI 3-9) to 17 months (95%CI 15-19) for treated patients. When all these factors were put in the multivariate models age and type of surgery remained significant. Patients older than 65 had a mortality risk eight times greater than patients 16-36 years old. The relative risk was 0.65 for total surgery compared with partial surgery, i.e. a decreased risk of 35%. Conclusions. Age and type of surgery had the strongest effect on the survival probability of patients with malignant CNS tumors.
|Issue number||4 SUPPL.|
|Publication status||Published - 2000|
ASJC Scopus subject areas
- Clinical Neurology